Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Questions Spray Sunscreen Safety, Efficacy & Monograph Status

Executive Summary

FDA could exclude increasingly popular spray sunscreens from the final monograph unless firms submit sufficient safety and efficacy data, according to an advanced notice of proposed rulemaking.
Advertisement

Related Content

Coppertone Innovates With Texture, Launching ‘Whipped’ Sunscreens
FDA Scorches Sunscreen Wipe Marketers With October Warning Letters
EWG's Abiding Sunscreen Concerns Cast Shadow Over 13 Kids' Formulas
EC Seeks Comment On Proposed Cosmetic Preservative, Colorant Bans
Energizer Weighs In On Spray-Sunscreen Monograph Viability, With Data
Spray Sunscreens Are Safe, Trade Groups Say; New Test Methods Not Needed
Industry Needs More Time To Comply With Sunscreen Testing, Labeling Rule
Proposed Spray Sunscreen Warnings A Gateway For Nano Tort Litigation?
FDA Strengthens Sunscreen Testing And Label Requirements
FDA Strengthens Sunscreen Testing And Label Requirements
Advertisement
UsernamePublicRestriction

Register

RS017629

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel